Elotuzumab: the first available immunotherapeutic arrow against relapsed-refractory Multiple Myeloma. (2017). European Journal of Oncology and Environmental Health, 22(2), 65-70. https://mattioli1885journals.com/index.php/EJOEH/article/view/6857